Identification of a human T lymphocyte surface protein associated with the E-rosette receptor by unknown
Brief Definitive Report 
IDENTIFICATION  OF  A  HUMAN  T  LYMPHOCYTE  SURFACE 
PROTEIN  ASSOCIATED  WITH  THE  E-ROSETTE  RECEPTOR 
BY MALEK  KAMOUN, PAUL J.  MARTIN,* JOHN  A.  HANSEN, 
MELISSA  A.  BROWN, ANTHONY  W.  SIADAK, ANO ROBERT  C.  NOWINSKI 
From the Fred Hutchinson Cancer Research Center; and the Puget Sound Blood Center, Seattle, Washington 
98104; and the Department of Medicine, Division of Oncology, University of Washington School of 
Medicine, Seattle, Washington 98195 
Human  thymus-dependent  lymphocytes  (T  cells)  are  defined by  their  ability to 
form  spontaneous  rosettes  (E-rosettes)  with  sheep  erythrocytes  (SRBC)  (1-3).  Re- 
cently, several murine  monoclonal  antibodies that  recognize distinct differentiation 
antigens on human T  cells have been described (4-11). We report here a  monoclonal 
antibody, designated 9.6, that identifies a  50,000-dalton surface protein that appears 
to be present on  all E-rosette-forming cells. Blocking and  lysostripping experiments 
indicate that this monoclonal antibody reacts either with the E  receptor itself or with 
a  closely associated structure. 
Materials  and  Methods 
Cells.  Mononuclear cells from peripheral blood (PBL) or bone marrow were obtained from 
normal volunteers and isolated by centrifugation over Ficoll-Hypaque (LSM; Litton Bionetics 
Inc., Kensington, Md.). T cells were enumerated by rosetting with 2-aminoethylisothiouronium 
bromide hydrobromide (AET)-treated SRBC (SRBC^v..r)  in medium (RPMI-1640) with  12% 
fetal calf serum (12). For the isolation of purified T cells, PBL were passed over nylon wool (11) 
and then incubated with SRBCA~--v. Rosette-forming T  cells (E  +) were separated from non-T 
cells (E-) by centrifugation over Ficoll-Hypaque. T  cells were recovered from the rosettes by 
lysis of SRBC in Tris-buffered 0.83%  ammonium  chloride. Normal human  thymocytes were 
prepared from thymus specimens obtained in the course of corrective open heart surgery from 
children < 14 yr old. Long-term-cultured T cells, stimulated by alloantigen, were maintained in 
medium supplemented with T  cell growth factor (TCGF) (13). 
A selected panel of cultured lymphoid cell lines was used for serological analysis. Included 
were leukemic T  cell lines (CEM, HSB2, 8402, Jurkat, Molt-4F, and KE37), the leukemic pre- 
B cell line NALM-6, Epstein-Barr virus-transformed B-lymphoid cell lines (PA-3, SB, 8392, 
HA, Swei), and the Burkitt's lymphoma ceil line Daudi. 
Leukemic blasts from peripheral blood of patients with acute lymphocytic leukemia (ALL), 
were separated over Ficoll-Hypaque, and cryopreserved. Cells were obtained either at presen- 
tation or relapse when the leukocyte count was >20,000/mm s and >90% of the cells were blasts. 
Subdivision of ALL into T  and null cell types was based on the clinical criterion of a thymic 
mass, and on determination of whether the leukemic blasts formed E-rosettes or expressed ia- 
like antigen. 
Immunizations,  Fusion, and  Screening.  The  clone  of hybrid  cells  producing  the  antibody 
described here was isolated from a previously described fusion experiment (9).  Briefly, spleen 
cells from  BALB/c mice immunized with human  peripheral blood lymphocytes were fused 
with BALB/c MOPC21 NSI/1 myeloma cells. Antibody production by hybrid cells was assayed 
by testing tissue culture supernates in a complement-dependent microcytotoxicity  assay against 
normal peripheral blood T  cells, a B-lymphoid cell line, and continuously cultured T  cells, all 
obtained  from  the  same  donor.  One  culture  fluid was  cytotoxic for  both  the  normal  and 
cultured T  cells but  nonreactive with  the autologous B-lymphoid cell line. Cells from  this 
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culture, designated 9.6, were serially cloned four times by limiting-dilution and then inoculated 
intraperitoneally  into  Pristane-primed  (Aldrich  Chemical  Co.,  Inc.,  Milwaukee,  Wis.) 
BALB/c mice for the production of antibody-containing ascites fluid. The immunoglobulin 
produced by the 9.6 hybrid was identified as IgG2b by immunodiffusion. 
Serological Analysis.  Methods  for  complement-dependent  microcytotoxicity, quantitative 
cytotoxicity (using trypan  blue as indicator), and  indirect  immunofluorescence assays have 
been  previously described (9,  11). A  fluorescein-conjugated affinity-purified goat anti-mouse 
IgG serum  (Litton Bionetics Inc.) was used for indirect immunofluorescence. In some experi~ 
ments rhodamine-conjugated goat  F(ab')2 fragments specific for mouse IgG were  used  (this 
reagent was generously provided by Dr. Shu Man Fu, The Rockefeller University, New York). 
Comparative studies were carried out using three additional monoclonal antibodies recognizing 
distinct markers  for human  lymphocytes. Antibody 9.3  reacts with  a  45,000-dahon  surface 
protein expressed by 70-80% of peripheral E + cells (9); antibody 10.2 reacts with a 65,000- to 
67,000-dahon  surface  protein expressed  by 85-95%  of peripheral blood  E + cells  (11);  and 
antibody 7.2 reacts with a framework determinant of the human Ia bimolecular complex (9). 
Blocking  of E  Rosette  Formation  and  Lysostrippmg.  Cells  were  incubated  in  medium  that 
contained monoclonal antibody for 30 min at 22°C and then washed three times. In blocking 
experiments, these cells were subsequently assayed for E  rosette formation.  In  lysostripping 
experiments, treated cells were incubated with  affinity-purified goat  anti-mouse IgG serum 
(fluorescein conjugated) for 45 rain at 37~'C, washed three times, and then  tested for rosette 
formation. 
Immune Prectpitation of Cell Membranes.  Cells of the leukemic T  cell line Jurkat were washed 
twice in  phosphate-buffered safine, pH  7.2,  and  surface labeled by  the  125I-lactoperoxidase 
method (14) with minor modification (15). Labeled ceils were disrupted in cell lysis buffer that 
contained 0.5% Nonidet P-40 (15) and 2% of the protease inhibitor aprotinin (Sigma Chemical 
Co., St. Louis, Mo.). The lysate was cleared of nonsolubilized cellular structures and free 125I by 
uhracentrifugation and chromatography on a  Sephadex G-25 column as described elsewhere 
(16). 
Before  use  in  immune  precipitation analysis,  the  cell  lysate  was  treated  by  sequential 
incubation (1 h each at 4°C) with AKR normal mouse serum (1:40 dilution) and Staphylococcus 
aureus, Cowan I strain (30 mg)  (17). The S.  aureus was removed from the reaction mixture by 
centrifugation at 1,500 g for 10 min. The concentration of sodium dodecyl sulfate (SDS) in the 
lysate was adjusted to 0.1% and the immune precip!tation reactions initiated by the addition 
6  of 5 #1 of appropriately diluted antibody to 95-#1 (I0  cpm) aliquots of radiolabeled lysate. The 
mixture was incubated for 1 h on ice and the reaction then terminated by fhe addition of 3.5 
mg S. aureus for 30 min on ice. The S. aureus pellet was washed five times in buffer that contained 
0.5%  NP-40 and 0.1% SDS (15).  Radiolabeled proteins bound to the pellet were extracted by 
incubation  with  50 #1  of sample electrophoresis buffer  (0.062  M  Tris-HCl,  2%  SDS,  10% 
glycerol, 5% 2-mercaptoethanol, and 0.02% bromphenol blue, pH 6.8)  for 5 min at  100°C and 
then  analyzed by polyacrylamide gel electrophoresis (PAGE)  in  the presence of SDS  (SDS- 
PAGE)  in  10%  slab  gels  (18).  Radiolabeled  bands  in  the  dried  gel  were  identified  by 
radioautography (Kodak NS-2T film [Eastman Kodak Co., Rochester, N. Y.] with GAFMED 
Rarex B Mid Speed intensifying screen [GAF Corp., New York] with exposure at -70°C) (19). 
Results and  Discussion 
The 9.6 antigen was present on peripheral blood T  cells and thymocytes, but was 
not detected on mononuclear cells of peripheral blood or bone marrow after removal 
ofT cells by E-rosetting (Table I). T  cells purified by passage over nylon wool followed 
by  centrifugation  of  E +  cells  over  Ficoll-Hypaque  were  >99%  positive  with  9.6 
antibody.  Thymocytes  were  also  >99%  positive  for  the  9.6  antigen.  Cells  from  B 
lymphoid lines were uniformly negative. 
A  high  degree of concordance  between  E-rosette formation and  expression of 9.6 
antigen  was  observed  in  testing  cells  from  a  variety  of sources  (Table  I).  Similar 
numbers of 9.6-positive and E + cells were found in PBL, thymus, bone marrow, and 
long-term-cultured T  cells. Expression of 9.6 antigen also correlated with E-rosetting 
in cells of leukemic T  cell lines. Only the E + leukemic T  cell lines 8402, Jurkat, and 
Molt-4F were 9.6 positive, each demonstrating equal numbers of E + and 9.6-positive KAMOUN  ET  AL.  BRIEF  DEFINITIVE  REPORT  209 
TABLE  I 
Comparison of the Number of E-Rosetting and Monoclonal Antibody 9.6-Positive Cells 
in Normal and Cultured Lymphoid Cells* 
Percent E ÷  Percent 9.6 positive 
Peripheral blood lymphocytes  72 
Purified T  cells  99 
Non-T cells  <1 
Thymocytes  >99 
Bone marrow cells  9  17 
T cell depleted  < 1 
B-lymphoid cell lines$§  <1 
Cultured T  cellsll  >99 
Leukemic T  cell lines§ 
GEM  < 1 
8402  23 
Jurkat  90 
HSB-2  < 1 
KE37  <1 
Moh-4F  17 
Mofi-4F,  E ÷ enriched  85 
Moh-4F, E  ÷ depleted  3 
(9)  68 (9) 
(5)  99 (5) 
(3)  <1 (3) 
(3)  >99 (3) 
(3)  10  15 (4) 
(2)  <1 (2) 
(7)  <l (7) 









* Assays for E-rosette forming cells E  ÷ were performed with SRBC^m-. Testing with 9.6 antibody 
was performed by indirect immunofluorescence. The number of donors tested is indicated in 
parentheses. Where appropriate, results are expressed as the mean (or range) of multiple samples. 
:~ NALM-6, Daudi, PA3, SB, 8392, HA and Swei. 
§ Cell  lines  CEM and PA3 were obtained from Dr.  D.  Mann,  National Institutes of Health, 
Betbesda, Md.;  HSB-2, SB,  and Jurkat  from Dr.  W.  D.  Peterson, Wayne State  University, 
Detroit,  Mich.;  8402,  8392,  Molt-4F,  and  NALM-6 from  Dr. J.  Minowada,  Roswell  Park 
Memorial Institute, Buffalo,  N. Y.; KE37 from Dr. S. M. Fu; and Daudi from Dr. W. Newman, 
Fred Hutchinson Cancer Research Center, Seattle, Wash. Derivation of B-lymphoid cell lines 
HA and Swei has been previously described (20). 
II Normal T  cells stimulated with alloantigen and cultured >3 mo in TCG Factor. 
TABLE II 
Effect of Antibody 9.6 on E-Rosette Formation 
Cells treated 
E-Rosette formation after incubation with 
antibody* 
Control  Antibody 10.2  Antibody 9.6 
Peripheral T cells:~  86  92  < 1 
Thymocytes  99  98  < 1 
Cultured T  cells  99  99  < 1 
Leukemic T cell line, Jurkat  92  96  < 1 
PHA blasts§  ND  94  < I 
* Results expressed  as the percent rosette-forming cells.  Ascites  fluids  that  contained' antibody 
10.2 or 9.6 were tested at a dilution of 1  : 1,000. Rosette inhibition with antibody 9.6 persisted  to 
a dilution of 1:64,000. ND, not determined. 
:~ Nylon wool-nonadherent peripheral blood lymphocytes. 
§ Nylon  wool-nonadherent peripheral blood  lymphocytes were cultured  for  72  h  in  complete 
medium with 10% pooled  human serum and 12 #g/ml phytohemagglutinin (PHA-P: Burrnughs 
Wellcome & Co.,  Research Triangle Park, N. C.). 
cells.  Molt-4F  cells,  enriched  for  E +  cells  were  9.6  positive,  whereas  Molt-4F  cells 
depleted  of E +  cells  were 9.6  negative.  Cells  from patients  with  T  cell  ALL  whose 
leukemic blasts  formed  E-rosettes  were 9.6  positive.  Leukemic  blasts  from  patients 
with null cell ALL were 9.6 negative. 
The association between the E receptor and the 9.6 antigen was further investigated 
by blocking experiments. Cells preincubated with antibody 9.6 did not form E-rosettes 
(Table II). Incubation with either of the two other monoelonal T  cell antibodies, 9.3 
(data not shown) or 10.2, did not inhibit  E-rosetting.  Rosette inhibition by antibody 
9.6 paralleled its activity in a complement-mediated cytotoxicity assay. 210  KAMOUN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  III 
Lysostripping 
Treated cells tested by indirect 
Lysostripping  E +  immunofluorescence:~ 
antibody* 
9.6  10.2 
None  94  94  91 
9.6  4  0  92 
1(I.2  95  77  0 
* Cells were incubated with monoclonal antibody diluted in medium for 0.5 h at  22°G 
and washed three times.  Cells  were then  incubated with fluorescein-conjugated  goat 
anti-mouse lgG serum for 45 min at 37°C and the washing was repeated. Fluorescein 
staining was detected only in polar caps. Rosetting was assayed with SRBG^m,, Numbers 
in the Table repre~nt the percentage of rosetting cells. 
:~ To determine whether any uncapped mouse immunoglobulin remained on  the cells 
after lysostripping,  cells were stained with rhodamine-conjugated goat F(ab')2 fragments 
specific  for mouse immunoglobulin. No rhodamine staining could be detected outside 
the polar caps.  Treated cells were also  tested  with 9.6 antibody and  10.2 antibody by 
indirect  immunofluorescence to determine whether the respective antigens had been 
completely capped.  The  rhodamine-conjugated antiserum  facilitated  distinction  be- 
tween staining of previously formed polar caps and circumferential staining of antigens 
that remained distributed on the cells. Numbers in the Table represent percent positive 
cells. 
Lysostripping  of cells  incubated  with  monoclonal  antibody  was  performed  to 
determine whether the E receptor and the 9.6 antigen could be distinguished by co- 
capping.  Cells  lysostripped  of 9.6  antigen  did  not  form  E-rosettes,  whereas  cells 
lysostripped of the  10.2  antigen were still capable of rosette formation  (Table III). 
Capping of antigen-antibody complexes appeared complete, as assessed by indirect 
immunofluorescence (Table III)  and  quantitative cytotoxicity (data  not  shown).  It 
appeared, therefore, that the failure of cells stripped of 9.6 antigen to form E rosettes 
was not a  result of residual  blocking antibody. When cells were lysostripped of 9.6 
antigen and then incubated in fresh medium at 37°C for 18 h, they again expressed 
9.6 antigen and formed E-rosettes. 
Results of precipitation assays with antibody 9.6 and an  12~I-labeled lysate of the 
leukemic T  cell line Jurkat are presented in Fig.  1. The antibody precipitated a single 
polypeptide  of -50,000  mol  wt.  In  this  same  assay  are  shown  the  results  with 
antibodies 9.3  and  10.2,  which  precipitated proteins of 45,000 and  67,000 daltons, 
respectively. The 45,000-dalton protein precipitated by 9.3 antibody was not associ- 
ated with flz-microglobulin. This was in contrast to that observed with precipitates 
formed  by  antibodies  against  HLA  heavy  chain  (W6/32)  and  fl2-microglobulin. 
Control reactions performed with normal mouse serum and monoclonal antibody 7.2 
against  human  Ia  antigen  failed  to  show  precipitation  with  the  cell  lysate.  In 
additional  precipitation assays with  12~I-labeled  lysates of normal T  cells  (data not 
shown), the 9.6 antibody demonstrated essentially similar results to those found with 
the Jurkat cell line, although the antigen precipitated from normal T  cells showed a 
slightly more disperse  pattern on  the  gel.  These results  suggested  that  the antigen 
precipitated by 9.6 may have variable glycosylation patterns on T cells from different 
sources.  Alternatively,  the  different  pattern  on  gels  might  reflect  mild  proteolytic 
degradation of the antigen that varied from one T  cell type to another. 
Summary 
We describe a new monoclonal murine antibody that reacts with a 50,000-mol wt 
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FtG.  1.  Radioimmune precipitation assays with monoclonal antibodies and a lzSI-surface-labeled 
lysate of the leukemic T cell line Jurkat. Aliquots of radiolabeled cell lysate were tested in immune 
precipitation assays with: (1)  normal mouse serum (1:50 dilution); (2)  monoclonal 7.2 antibody 
from ascites fluid (1:500) which recognizes a monomorphic determinant of human la antigens (9); 
(3) rabbit anti-human/32-microglobulin  serum (Dakopatts,  Copenhagen, Denmark; 1:50 dilution); 
(4) monoclonal antibody W6/32 (Allied Chemical Corp., Morristown,  N.J.;  1:100 dilution) which 
recognizes a  monomorphic determinant of the HLA-A,B,C  heavy chain (21); (5) monoclonal 9.3 
antibody from ascites fluid (1:500 dilution) which recognizes a 45,000-dahon  protein specific for T 
cells (9); (6) monoclonal 10.2 antibody from ascites fluid (1:500 dilution) which recognizes a 65,000- 
67,000 dalton protein specific for T  ceils (11); and (7) monoclonal 9.6 antibody from ascites fluid 
(1:500 dilution). Immune precipitates  were collected on S. aureus, eluted in electrophoresis  buffer 
that contained 2-mercaptoethanol, and analyzed by SDS-PAGE. Radioautography of the dried gel 
was enhanced for 2 d on x-ray intensifying  screens. 
antigen is either identical to or closely associated  with the  E  receptor because of (a) 
the high degree of concordance between E-rosette formation and 9.6 antigen expres- 
sion, (b) the inhibition of rosette formation by preincubation of cells with 9.6 antibody, 
and (c) the observed failure of cells lysostripped of 9.6 antigen to form E-rosettes. This 
last finding suggests cocapping of 9.6 antigen and the E  receptor. 
Received  for publication 1 August  1980 and in revised  form 3 November 1980. 
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